Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Association Between Glutamate Blockade and Fatigue in Patients With Multiple Sclerosis.
Poster abstracts from the third international symposium on gait and balance in multiple sclerosis: selecting the right measures.
Comparative validity of accelerometer based measures of physical activity for people with multiple sclerosis.
Therapeutic effet of phase ii enzyme inducers in experimental allergic encephalomyelitis (eae).
[Vitamin D tweets light to genes in multiple sclerosis].
FTY720 (Fingolimod) attenuates basal and sphingosine 1-phosphate-evoked thyroid cancer cell invasion.
G protein-coupled receptor 30 contributes to improved remyelination after cuprizone-induced demyelination.
Application of the fuzzy logic concept in the multiple sclerosis functional composite for scoring the progress of multiple sclerosis.
Opexa Therapeutics Announces Tcelna™ as New Brand Name for MS Therapy
Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model.
Genetic targeting of microglia.
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
Fingolimod induces neuroprotective factors in human astrocytes.
Contribution of MicroRNAs to autoimmune diseases.
Ten-year follow-up shows efficacy of Sanofi's MS drug Lemtrada
Frequency and economic impact of comorbid cardiac conditions with multiple sclerosis.
Change of fate commitment in adult neural progenitor cells subjected to chronic inflammation.
Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM.
[Processing speed in relapsing-remitting multiple sclerosis: the role played by the depressive symptoms].
Polyphenols: multipotent therapeutic agents in neurodegenerative diseases.
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
Pediatric multiple sclerosis: update in diagnosis and management.
Interplaying factors that effect multiple sclerosis causation and sustenance.
MS Patients Report Excellent Compliance with Oral Prednisone for Acute Relapses.
Viruses and Multiple Sclerosis.
Pages
« first
‹ previous
…
255
256
257
258
259
260
261
262
263
…
next ›
last »